

Microbial Imbalance in Atopic Dermatitis: The Role of the Skin Microbiome in Disease Progression and Treatment

Jenifer Lancy A^{1*}, Priyanka Anand², Sivalakshmi B², Nikkisha Sree S², Jaisree R², Arpita. J², Dona. S. Jayan²

¹Department of Varmam, Pura maruthuvam and sirappu maruthuvam, Santhigiri Siddha Medical College, Trivandrum, Kerala.

²Under graduate students, Santhigiri Siddha Medical College, Trivandrum, Kerala.

*Corresponding Author

Jenifer Lancy A.

Associate professor, Department of Varmam, Pura maruthuvam and sirappu maruthuvam, Santhigiri Siddha Medical College, Trivandrum, Kerala.

Article History

Received: 01.09.2024

Accepted: 19.09.2024

Published: 03.10.2024

Abstract: -

Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition that is closely associated with an imbalance in the skin microbiome. This imbalance, also known as dysbiosis, leads to the overgrowth of pathogenic microorganisms, particularly *Staphylococcus aureus*, while beneficial bacteria such as *Staphylococcus epidermidis* are diminished. The relationship between the microbiome and the immune system plays a crucial role in the pathogenesis and progression of AD.

Objective: The aim of this article is to review the role of the skin microbiome in the development and management of atopic dermatitis. The article explores microbial composition, dysbiosis, immune interactions, environmental and genetic factors, and current therapeutic strategies.

Methods: A comprehensive review of recent studies was conducted to evaluate the impact of the skin microbiome on AD. The review focuses on microbial shifts, the role of *S. aureus*, immune system interactions, and potential treatments targeting the skin microbiome.

Results: The findings highlight that microbial dysbiosis, particularly the dominance of *S. aureus*, contributes to the severity of AD. Therapeutic approaches targeting the microbiome, such as the use of probiotics, prebiotics, antimicrobial peptides, and microbiome transplants, show promise in managing AD symptoms.

Conclusion: The skin microbiome plays a critical role in the pathogenesis of atopic dermatitis. Restoring microbial balance through targeted therapies could offer new avenues for effective treatment and management of AD.

Keywords: Atopic dermatitis, Skin microbiome, Dysbiosis, *Staphylococcus aureus*, Microbiome therapy, Inflammation.

Cite this article:

Jenifer, L. A., Anand, P., Sivalakshmi, B., Nikkisha, S. S., Jaisree, R., Arpita, J., Jayan, D. S., (2024). Microbial Imbalance in Atopic Dermatitis: The Role of the Skin Microbiome in Disease Progression and Treatment. *ISAR Journal of Medical and Pharmaceutical Sciences*, 2(10), 13-15.

1.0 Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent eczematous lesions, pruritus, and significant disruption of the skin barrier function. Affecting both children and adults, it is one of the most common skin diseases globally, with a prevalence of 15-30% in children and 2-10% in adults (1). The pathogenesis of AD is multifactorial, involving genetic predisposition, immune dysregulation, environmental factors, and importantly, alterations in the skin microbiome. The skin, as the largest organ, harbors a complex microbial community that plays a critical role in maintaining skin health. Disruptions in

this microbial equilibrium, often referred to as dysbiosis, have been closely linked to various dermatological conditions, including atopic dermatitis (2).

The skin microbiome is composed of bacteria, fungi, viruses, and mites, with bacteria such as *Staphylococcus*, *Corynebacterium*, *Propionibacterium*, and *Cutibacterium* being dominant members. Among these, *Staphylococcus aureus* has been identified as a key pathogen in the exacerbation of AD. Numerous studies have shown that AD patients have increased colonization of *S. aureus* on affected skin sites, correlating with disease severity (3). This overgrowth of *S. aureus* not only exacerbates inflammation by

releasing toxins and superantigens but also competes with beneficial skin microbes, further disrupting the skin barrier and immune response.

In contrast, beneficial microbes like *Staphylococcus epidermidis* are often reduced in AD patients, leading to an imbalance that favors pathogenic colonization. The protective role of *S. epidermidis* lies in its ability to produce antimicrobial peptides (AMPs) that inhibit *S. aureus* overgrowth and enhance skin barrier function (4). This intricate balance between protective and pathogenic microbes underscores the importance of the skin microbiome in maintaining skin homeostasis and its potential role in disease pathogenesis.

Recent advancements in molecular techniques, such as next-generation sequencing, have provided a deeper understanding of the skin microbiome's composition and its role in AD. These studies suggest that therapeutic strategies aimed at restoring microbial balance, such as probiotics, prebiotics, or bacteriotherapy, could offer novel treatments for AD (5). The potential to manipulate the skin microbiome represents a promising frontier in the management of chronic skin conditions.

The aim of this article is to explore the role of the skin microbiome in the pathogenesis of atopic dermatitis, focusing on microbial dysbiosis, the impact of *Staphylococcus aureus* colonization, and emerging therapeutic strategies aimed at modulating the skin microbiome to treat AD.

2.0 The Skin Microbiome: Composition and Function

The skin microbiome is a complex community of microorganisms, including bacteria, fungi, viruses, and mites, that coexist on human skin. The composition of the skin microbiome varies between individuals and is influenced by factors such as genetics, environment, diet, and personal hygiene. Major bacterial species found on healthy skin include *Staphylococcus epidermidis*, *Corynebacterium*, and *Propionibacterium* species (6). These microorganisms play a critical role in maintaining skin homeostasis by preventing colonization by pathogenic bacteria, contributing to the immune system's function, and supporting the skin's barrier function (7). The skin microbiome is not static but dynamic, changing in response to environmental stimuli and physiological conditions. A balanced microbiome protects against external infections and prevents inflammation by interacting with the immune system (8).

3.0 Microbiome Dysbiosis in Atopic Dermatitis

Dysbiosis refers to an imbalance in the microbial community, often characterized by an overgrowth of pathogenic species and a reduction in beneficial microbes. In the case of atopic dermatitis (AD), dysbiosis is commonly observed, with studies showing a significant reduction in microbial diversity on the skin of AD patients (9). The dominance of *Staphylococcus aureus* is particularly notable, as this pathogen often overpopulates the skin of AD sufferers, contributing to disease flares and severity. The loss of beneficial microbes such as *Staphylococcus epidermidis*, which usually inhibit the growth of pathogenic species, exacerbates this imbalance (10). Dysbiosis is both a consequence of AD and a factor that worsens the disease, creating a vicious cycle where inflammation and microbial imbalance feed into each other.

4.0 Staphylococcus aureus and Its Role in Atopic Dermatitis

Staphylococcus aureus plays a significant role in the exacerbation of atopic dermatitis. This bacterium is capable of colonizing eczematous skin lesions and releasing toxins, known as superantigens, which can activate the immune system and induce inflammation (11). The colonization of *S. aureus* is associated with disease severity, and patients with higher *S. aureus* counts tend to experience more intense symptoms. Additionally, *S. aureus* can disrupt the skin barrier by degrading essential proteins, such as filaggrin, and facilitating the penetration of allergens and irritants (12). The overgrowth of *S. aureus* in AD patients suggests that targeting this bacterium could be a key therapeutic strategy.

5.0 Interactions between the Microbiome and the Immune System in AD

The skin's immune system plays a crucial role in maintaining homeostasis by interacting with the microbiome. In atopic dermatitis, this interaction becomes dysregulated, leading to chronic inflammation. The immune system, particularly T-helper cells, recognizes certain microbial signals and responds by producing cytokines. In AD, the immune response is skewed toward a Th2-dominant response, which promotes allergic inflammation (13). Dysbiosis, especially the dominance of *Staphylococcus aureus*, further aggravates this imbalance by producing toxins that amplify the immune response. Conversely, beneficial microbes such as *Staphylococcus epidermidis* can help modulate the immune system, reducing inflammation and promoting skin healing (14).

6.0 Environmental and Genetic Factors Affecting the Skin Microbiome in AD

Environmental factors, such as climate, pollution, and the use of personal care products, can significantly influence the skin microbiome. Dry skin, which is common in AD patients, creates a conducive environment for *S. aureus* colonization. Excessive hygiene practices or the use of harsh cleansers can strip the skin of its natural oils, further disrupting the microbiome (15). Genetic predispositions also play a role, particularly mutations in the filaggrin gene, which are common in AD patients. Filaggrin is essential for maintaining the skin barrier, and its deficiency can lead to increased transepidermal water loss and easier colonization by pathogenic bacteria (16). These environmental and genetic factors create a delicate balance, where even small disruptions can lead to significant microbial imbalances.

7.0 Current and Emerging Therapies Targeting the Skin Microbiome

Current treatments for atopic dermatitis primarily focus on reducing inflammation and restoring the skin barrier. However, new therapeutic strategies are emerging that specifically target the skin microbiome. These include the use of probiotics and prebiotics, which aim to restore microbial balance by promoting the growth of beneficial bacteria. Some studies have shown that topical applications of certain bacterial strains, such as *Staphylococcus hominis*, can inhibit the growth of *S. aureus* and reduce AD symptoms (17). Antimicrobial peptides (AMPs) and natural oils are also being explored as treatments, as they can

selectively kill pathogenic bacteria while preserving beneficial microbes. Another emerging approach is microbiome transplantation, where healthy skin bacteria are transplanted to affected individuals to restore balance (18).

8.0 Challenges and Limitations in Microbiome-Based Approaches for AD

Despite the promise of microbiome-based therapies, there are several challenges to their widespread adoption. One major issue is the variability in skin microbiome profiles among AD patients, making it difficult to develop one-size-fits-all treatments (19). Additionally, the long-term effects of introducing new microbial species onto the skin are still not fully understood. Regulatory hurdles also exist, as microbiome therapies are considered novel treatments and must undergo rigorous testing for safety and efficacy. Production challenges, such as ensuring the stability of microbial formulations, are also significant obstacles (20).

9.0 Future Directions in Microbiome Research for Atopic Dermatitis

Research into the skin microbiome's role in atopic dermatitis is still in its early stages, but the potential for personalized treatments is promising. Advances in sequencing technologies are allowing researchers to identify specific microbial signatures associated with different stages of AD, opening the door to personalized microbiome therapies. In the future, treatments could be tailored based on an individual's unique microbiome profile, leading to more effective and targeted therapies (21). Additionally, integrating microbiome-based approaches with existing treatments, such as emollients and corticosteroids, could provide a more holistic approach to AD management.

10.0 Conclusion

The skin microbiome plays a critical role in the pathogenesis of atopic dermatitis, with dysbiosis contributing to disease progression. Therapeutic strategies that target the skin microbiome, such as probiotics, antimicrobial peptides, and microbiome transplants, offer promising new avenues for treatment. However, more research is needed to fully understand the complex interactions between the microbiome, the immune system, and environmental factors in AD. Personalized microbiome therapies hold great promise for the future, potentially revolutionizing the treatment of atopic dermatitis.

References

- Nutten S. (2015). Atopic dermatitis: global epidemiology and risk factors. *Ann Nutr Metab.* 66 Suppl 1:8-16. doi: 10.1159/000370220.
- Kong HH, Segre JA. (2012). Skin microbiome: looking back to move forward. *J Invest Dermatol.* 132(3 Pt 2):933-9. doi: 10.1038/jid.2011.417.
- Geoghegan JA, Irvine AD, Foster TJ. (2018). *Staphylococcus aureus* and Atopic Dermatitis: A Complex and Evolving Relationship. *Trends Microbiol.* 26(6):484-497. doi: 10.1016/j.tim.2017.11.008.
- Belkaid Y, Segre JA. (2014). Dialogue between skin microbiota and immunity. *Science.* 346(6212):954-9. doi: 10.1126/science.1260144.
- Nakatsuji T, Gallo RL. (2019). The role of the skin microbiome in atopic dermatitis. *Ann Allergy Asthma Immunol.* 122(3):263-269. doi: 10.1016/j.anai.2018.12.001.
- Grice EA, Segre JA. (2011). The skin microbiome. *Nat Rev Microbiol.* 9(4):244-53. doi: 10.1038/nrmicro2537.
- Sanford JA, Gallo RL. (2013). Functions of the skin microbiota in health and disease. *Semin Immunol.* 25(5):370-7. doi: 10.1016/j.smim.2013.09.005.
- Belkaid Y, Segre JA. (2014). Dialogue between skin microbiota and immunity. *Science.* 346(6212):954-9. doi: 10.1126/science.1260144.
- Kong HH, Oh J, Deming C, et al. (2012). Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res.* 22(5):850-9. doi: 10.1101/gr.131029.111.
- Nakatsuji T, Chiang HI, Jiang SB, et al. (2013). The microbiome extends to subepidermal compartments of normal skin. *Nat Commun.* 4:1431. doi: 10.1038/ncomms2416.
- Williams MR, Gallo RL. (2015). The role of the skin microbiome in atopic dermatitis. *Curr Allergy Asthma Rep.* 15(9):65. doi: 10.1007/s11882-015-0567-4.
- Ong PY, Leung DY. (2016). Bacterial and viral infections in atopic dermatitis: a comprehensive review. *Clin Rev Allergy Immunol.* 51(3):329-37. doi: 10.1007/s12016-016-8552-x.
- Weidinger S, Novak N. (2016). Atopic dermatitis. *Lancet.* 387(10023):1109-22. doi: 10.1016/S0140-6736(15)00149-X.
- Paller AS, Kong HH, Seed P, et al. (2019). The microbiome in patients with atopic dermatitis. *J Allergy Clin Immunol.* 144(2):350-8. doi: 10.1016/j.jaci.2019.06.032.
- Bieber T. (2008). Atopic dermatitis. *N Engl J Med.* 358(14):1483-94. doi: 10.1056/NEJMr074081.
- Brown SJ, McLean WHI. (2012). Eczema genetics: current state of knowledge and future goals. *J Invest Dermatol.* 132(3):527-30. doi: 10.1038/jid.2011.403.
- Myles IA, Earland NJ, Anderson ED, et al. (2018). First-in-human topical microbiome transplantation with *Roseomonas mucosa* for atopic dermatitis. *JCI Insight.* 3(9). doi: 10.1172/jci.insight.120608.
- Huang JT, Abrams M, Tloutan B, et al. (2009). Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics.* 123(5). doi: 10.1542/peds.2008-2217.
- Lehmann S, Giunta RE. (2020). Skin microbiome and atopic dermatitis: implications for treatment. *J Dtsch Dermatol Ges.* 18(6):565-73. doi: 10.1111/ddg.14147.
- Naik S, Bouladoux N, Wilhelm C, et al. (2012). Compartmentalized control of skin immunity by resident commensals. *Science.* 337(6098):1115-9. doi: 10.1126/science.1225152.
- McAleer MA, Irvine AD. (2013). The multifunctional role of filaggrin in allergic skin disease. *J Allergy Clin Immunol.* 131(2):280-91. doi: 10.1016/j.jaci.2012.12.668.